About

Maya Capoor Evans, M.D., is an Associate Clinical Professor in the Department of Physical Medicine and Rehabilitation at UC Davis Health. Her clinical interests include pediatric rehabilitation medicine, with a focus on conditions such as spina bifida, cerebral palsy, spasticity, brain injury, and adaptive sports and recreation. Dr. Evans aims to provide excellent care to children and their families to maximize function and independence. She completed her undergraduate studies with a B.A. in Biology from Barnard College, Columbia University, and earned her M.D. from Rutgers - New Jersey Medical School. Her postgraduate training includes an internship in Physical Medicine and Rehabilitation at Atlantic Health System, a residency at Rutgers - NJMS/Kessler Institute for Rehabilitation, and a fellowship in Pediatric Rehabilitation Medicine at Rutgers - NJMS/Children's Specialized Hospital. Dr. Evans has been recognized as a top doctor by Sacramento Magazine and has received several awards for her teaching and research, including the David D. Kilmer Outstanding Faculty Teaching Award at UC Davis and the Robert Boyle Teacher of the Year at the Medical College of Wisconsin.

Research topics

• Biology
• Cancer research
• Internal medicine
• Medicine
• Pharmacology
• Biochemistry
• Chemistry
• Oncology
• Cell biology
• Immunology

Selected publications

• A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention

  ACS Central Science · 2026-05-13

  articleOpen access
  PublisherDOI

• Figure S6 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

  2025-11-25

  articleOpen accessSenior author

  <p>CDCP1 mRNA expression is not associated with overall survival. Kaplan–Meier survival analyses were performed on quartiles of CDCP1 mRNA expression with overall survival as the endpoint. p > 0.05 in both public datasets for which overall survival data were available.</p>

  PublisherOA PDFDOI

• Figure S8 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

  2025-11-25

  articleOpen accessSenior author

  <p>CDCP1 mRNA is not correlated NECTIN4 or TROP2 mRNA, related to Figure 2C. Spearman correlation analyses were performed between CDCP1 and NECTIN4 or TROP2 for the Seiler, Sjodahl 2017, and Sjodahl 2012 datasets, with p values and correlation coefficients shown. Points are colored by consensus subtype as in Figure 1.</p>

  PublisherOA PDFDOI

• 674 Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving ¹ ⁷ ⁷ Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response

  Regular and Young Investigator Award Abstracts · 2025-11-01

  articleOpen access
  PublisherOA PDFDOI

• Table S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

  2025-11-25

  articleOpen accessSenior author

  <p>CDCP1 mRNA is overexpressed in basal/squamous subtypes of bladder cancer, related to Figure 1A-D. Pairwise comparisons of CDCP1 expression between bladder cancer consensus subtypes using the Wilcoxon rank-sum test across four different datasets are shown.</p>

  PublisherDOI

• Supplementary Data from Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies

  2025-01-15

  preprintOpen access

  <p>Supplemental Data and Figures</p>

  PublisherDOI

• Figure S4 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

  2025-11-25

  articleOpen accessSenior author

  <p>CDCP1 mRNA expression in locally-advanced vs metastatic patients, from the IMvigor210 dataset. p=0.55 by Wilcoxon test, n=316 patients.</p>

  PublisherOA PDFDOI

• Figure S7 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

  2025-11-25

  articleOpen accessSenior author

  <p>A summary of the data from saturation binding assays used to calculate Bmax and receptor number per cell for bladder cancer cell lines. The data are representative of two independent assays. Data are reported as mean ± standard deviation.</p>

  PublisherOA PDFDOI

• Figure S5 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

  2025-11-25

  articleOpen accessSenior author

  <p>CDCP1 mRNA expression by site of biopsy, from the IMvigor210 dataset. p = 0.075 by Kruskal-Wallis test, n=348 samples</p>

  PublisherOA PDFDOI

• Figure S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

  2025-11-25

  articleOpen accessSenior author

  <p>CDCP1 mRNA expression by pathologic stage in the TCGA dataset. p=0.72 by Kruskal-Wallis test.</p>

  PublisherOA PDFDOI

Frequent coauthors

• Charles Truillet

  Commissariat à l'Énergie Atomique et aux Énergies Alternatives

  191 shared

• James A. Wells

  112 shared

• Ning Zhao

  110 shared

• Felix Y. Feng

  100 shared

• Jonathan Chou

  96 shared

• Emily A. Egusa

  University of California, San Francisco

  92 shared

• Yung-Hua Wang

  90 shared

• Shalini Chopra

  University of California, San Francisco

  90 shared

Labs

• UC Davis Health Physical Medicine and RehabilitationPI

Awards & honors

• Sacramento Magazine: Top Doctors: Physical Medicine and Reha…
• David D. Kilmer Outstanding Faculty Teaching Award, Departme…
• Robert Boyle Teacher of the Year, Department of Physical Med…
• Physical Medicine & Rehabilitation Research Award, Rutgers-N…
• Resident as Teacher Award, Rutgers-NJMS/Kessler, 2008